Biotech Co.* (Country; Symbol)

Pharma Co. (Country)


Terms/Details (Date)

Aero Pharmaceuticals Inc.*

Akorn Inc.

Akorn will provide contract manufacturing services for Aero

Details on the terms and products were not disclosed (5/6)

Avanir Pharmaceuticals Inc. (AMEX:AVN)

Gerolymatos Group of Companies (Greece)

Gerolymatos got exclusive rights to Avanir's docosanol 10% cream in Greece, Cyprus, Turkey and Romania

Avanir will receive a data-transfer fee, a potential milestone payment and royalties on any sales of the product, which is sold in the U.S. as Abreva for cold sores (6/14)

Carrington Laboratories Inc. (CARN)

Medline Industries Inc.

Extension of deal under which Medline will sell Carrington's wound and skin-care products

The deal, set to expire in November 2005, was extended through November 2008; Carrington gets a $1.25M royalty paymentand will continue manufacturing products (4/22)

Corixa Corp. (CRXA)

Australian Nuclear Science and Technology Organization (Australia)

ANSTO got exclusive rights to develop and sell Bexxar in much of the Australia-Asia region and coexclusive rights in Japan, South Korea and Taiwan

Under the 12-year deal, ANSTO will pay Corixa an up-front licensing fee and regulatory milestone payments, as well as payments based on sales volume and royalties on sales (5/19)

Genmab A/S

DSM Biologics

DSM will produce a commercial supply of HuMax-CD4

DSM will manufacture Genmab's antibody (Denmark; CSE:GEN) for T-cell lymphoma, both for clinical trials and subsequent commercialization (6/1)

Guilford Pharmaceuticals Inc. (GLFD)

Link Pharmaceuticals Ltd. (UK)

Link will distribute the Gliadel Wafer in Germany, Switzerland, France, Benelux and Austria

Link already sells the product for brain cancer in the UK; Guilford got $500,000 up front and could get up to $2M in milestone payments; Link is responsible for getting approvals in the covered countries (5/17)

Isotechnika Inc. (Canada; TSE: ISA)

Lonza Group Ltd. (Switzerland)

Lonza will manufacture Isotechnika's trans-ISA247 for upcoming clinical trials

The companies formalized a manufacturing deal; terms were not disclosed (6/8)

Matritech Inc. (AMEX:MZT)

Inverness Medical Innovations Inc.

Deal for the distribution of Matritech's NMP22 Test Kit for cancer detection

Inverness subsidiary Wampole Laboratories LLC got exclusive rights to sell to hospitals and laboratories in the U.S. (6/7)

MedImmune Inc. (MEDI)

Henry Schein Inc.

Henry Schein was named exclusive U.S. distributor of FluMist for the upcoming flu season

MedImmune will oversee all sales and mar- keting activities for FluMist, whose price was cut in half to $23.50 per dose; terms were not disclosed (6/15)

Pharmion Corp. (PHRM)

Ash Stevens Inc.

Ash Stevens got FDA approval to manufacture 5-azacitidine for Pharmion's Vidaza

Vidaza was approved May 20 for the treat- ment of myelodysplastic syndromes (5/21)

Pierce Biotechnology Inc.*

Tecan Group Ltd. (Switzerland)

Agreement to develop and co- market high-throughput screening solutions with fluorescence lifetime technology

They will combine technologies in the effort, and share product information and support; terms were not disclosed (5/17)

RheoGene Inc.*

New England Biolabs

NEB licensed rights to RheoGene's RheoSwitch inducible gene regulation technology

NEB can develop and distribute research kits and related products based on the technology, and got nonexclusive rights to develop combination research products that incorporate the technology (6/8)


# The information in the chart does not cover agricultural agreements or those between biotech companies.

* Private companies are indicated with an asterisk.

Unless otherwise noted, stock symbols listed are on the Nasdaq market.

AMEX = American Stock Exchange; CSE = Copenhagen Stock Exchange; TSE = Toronto Stock Exchange.